Skip to main content
Figure 2 | BMC Medicine

Figure 2

From: Transforming growth factor β1 inhibits bone morphogenic protein (BMP)-2 and BMP-7 signaling via upregulation of Ski-related novel protein N (SnoN): possible mechanism for the failure of BMP therapy?

Figure 2

Alterations in gene expression in primary human osteoblasts after treatment with recombinant human bone morphogenic protein (rhBMP)-2, rhBMP-7 or recombinant human transforming growth factor β 1 (rhTGFβ 1 ). Densitometric analysis (N = 3; n = 6) of reverse transcription polymerase chain reaction (RT-PCR) signals from primary human osteoblasts treated with 50 ng/ml rhBMP-2 or rhBMP-7 ± 5 ng/ml rhTGFβ1 for 72 h. Significant expression changes were observed in (A) R-Smad1, (B) I-Smad6, (C) activin receptor-like kinase (Alk)1, (D) TGFβ receptor II (TGFβRII), (E) Smad7 and (F) Ski-related novel protein N (SnoN). All other genes investigated were not significantly changed by rhBMP-2, rhBMP-7 or rhTGFβ1. *P < 0.05; **P < 0.01; ***P < 0.001 as compared to untreated cells.

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us